Concept: BDS_DR_CALUX in the ANALYS_MET vocabulary

Back to vocabulary

Concept URI	https://kodlistor.miljodatasamverkan.se/def/vocabulary/DATA_MATVARDE/ANALYS_MET/BDS_DR_CALUX
Preferred label	BDS_DR_CALUX
Definition	BDS-DR CALUX. Analytical method of BioDetection Systems (BDS): Bioassay detection of AhR (aryl-hydrocarbon receptor/dioxinreceptor)-activity coupled to presence of dioxins (PCDD/PCDF/dl-PCB). The samples were freeze dried, extracted with ASE (accelerated solvent extraction) with acetone/hexane (10%/90% v/v) followed by an additional acid silica column clean-up, restituted in DMSO (dimethylsulfoxid) and subsequently measured in the CALUX bioassay. The DR CALUX bioassay comprise a rat hepatoma cell line (H4IIE), incorporating the firefly luciferase gene coupled to Dioxin Responsive Elements (DREs) as a reporter gene. Following binding of dioxin compounds to the intracellular dioxin receptor, the ligand-receptor complex binds to and activates the DRE followed by expression of dioxins and luciferace. By addition of substrate for luciferase, light is emitted which is measured in a luminometer. The amount of light produced is proportional to the amount of ligand-specific receptor binding, which is benchmarked against the relevant reference compounds; for DR CALUX: 2,3,7,8-TCDD. The amount of light of the samples is interpolated in the curve to obtain the reference equivalents. (Van der Burg, B., Van der Linden, S.C., Man, H.Y., Winter, R., Jonker, L., Van Vugt-Lussenburg, B., Brouwer, A. (2013) A panel of quantitative CALUX® reporter gene assays for reliable high throughput toxicity screening of chemicals and complex mixtures. In “High throughput screening methods in toxicity testing” (P. Steinberg, ed). John Wiley and Sons, Inc. New York. ISBN 9781118065631 pp. 519-532)
Notation
Status	Valid
Status Modified	2025-07-08
Accepted Date	2025-07-08
Not Accepted Date